Viridian Therapeutics’ thyroid eye disease drug meets late-stage study goal
Viridian Therapeutics said on Monday its experimental drug to treat chronic thyroid eye disease (TED) met the main goal of a late-stage study, sending the company’s shares up more than 13% in premarket trading.